Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SY 005

Next Previous
Drug Profile

SY 005

Alternative Names: Annexin A5 based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals; Dianexin based therapeutics - Lawson Health Research Institute/Yabao Pharmaceuticals; Recombinant human annexin A5; SY-005

Latest Information Update: 28 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lawson Health Research Institute; Yabao Pharmaceutical Group
  • Class Biological peptides; Calcium binding proteins; Recombinant fusion proteins
  • Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sepsis

Most Recent Events

  • 28 May 2022 No recent reports of development identified for phase-I development in Sepsis in China (IV, Injection)
  • 24 May 2021 Yabao Pharmaceuticals plans a phase II trial for Sepsis (In adults, In the elderly) (IV) in July 2021 (NCT04898322)
  • 10 Feb 2021 Lawson Health Research Institute, Ontario Ministry of Colleges and Universities and London Health Sciences Foundation plan the phase I AX-COVID trial for Sepsis and severe COVID-19 infections in Canada (IV, Infusion) (NCT04748757), in March 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top